CSL:ASXCSL Limited Analysis
Data as of 2026-07-31 - not real-time
A$123.06
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
CSL Limited is trading above its short‑ and medium‑term moving averages while remaining below its long‑term average, suggesting a short‑term upside within a broader downtrend. The relative strength index sits in a neutral zone and the MACD has turned bullish, reinforcing a modest technical bias to the upside. However, the stock is experiencing a pronounced price decline of more than half over the past year and a substantial year‑to‑date drop, reflecting eroded market confidence. Volatility is elevated, yet the beta is exceptionally low, indicating that price swings are largely company‑specific rather than market‑driven. Fundamentals show a price‑to‑earnings multiple far below the industry average and a discounted cash‑flow model that points to a meaningful upside potential, while the dividend yield remains attractive with a payout ratio well under half of earnings. The balance sheet carries considerable debt relative to equity, but cash flow generation and a solid dividend policy suggest the dividend is sustainable. Analyst sentiment remains positive, with a consensus rating of buy, implying that many view the current price as a buying opportunity despite recent weakness.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price near resistance with limited upside in the near term
- elevated short‑term volatility
- recent sharp sell‑off eroding momentum
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- valuation gap versus peers and DCF upside
- attractive dividend yield and sustainable payout
- technical indicators turning bullish
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- low beta reducing systematic risk
- strong cash flow and dividend sustainability
- global diversification across therapeutic segments
Key Metrics & Analysis
Financial Health
Revenue Growth-1.80%
Profit Margin9.06%
P/E Ratio13.9
ROE6.66%
ROA6.58%
Debt/Equity54.44
P/B Ratio2.2
Op. Cash FlowA$3.6B
Free Cash FlowA$1.8B
Industry P/E29.4
Technical Analysis
TrendNeutral
RSI55.8
SupportA$113.75
ResistanceA$128.99
MA 20A$121.96
MA 50A$112.36
MA 200A$148.00
MACDBullish
VolumeStable
Fear & Greed Index91.54
Valuation
Fair ValueA$28.66
Target PriceA$138.88
Upside/Downside12.85%
GradeUndervalued
TypeValue
Dividend Yield3.46%
Risk Assessment
Beta0.01
Volatility36.30%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.